

# Mark Pimentel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2691286/publications.pdf>

Version: 2024-02-01

261  
papers

11,458  
citations

29994

54  
h-index

31759

101  
g-index

271  
all docs

271  
docs citations

271  
times ranked

6194  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. <i>New England Journal of Medicine</i> , 2011, 364, 22-32.	13.9	880
2	Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2000, 95, 3503-3506.	0.2	649
3	Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. <i>American Journal of Gastroenterology</i> , 2003, 98, 412-419.	0.2	586
4	Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. <i>American Journal of Gastroenterology</i> , 2017, 112, 775-784.	0.2	525
5	The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome. <i>Annals of Internal Medicine</i> , 2006, 145, 557.	2.0	417
6	Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G1089-G1095.	1.6	361
7	ACG Clinical Guideline: Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 17-44.	0.2	341
8	A Systematic Review of Diagnostic Tests for Small Intestinal Bacterial Overgrowth. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1443-1454.	1.1	248
9	ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. <i>American Journal of Gastroenterology</i> , 2020, 115, 165-178.	0.2	224
10	Methane production during lactulose breath test is associated with gastrointestinal disease presentation. <i>Digestive Diseases and Sciences</i> , 2003, 48, 86-92.	1.1	216
11	Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2016, 151, 1113-1121.	0.6	209
12	Methane and the Gastrointestinal Tract. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2135-2143.	1.1	185
13	Methanogens, Methane and Gastrointestinal Motility. <i>Journal of Neurogastroenterology and Motility</i> , 2014, 20, 31-40.	0.8	183
14	The Degree of Breath Methane Production in IBS Correlates With the Severity of Constipation. <i>American Journal of Gastroenterology</i> , 2007, 102, 837-841.	0.2	181
15	The Prevalence of Overgrowth by Aerobic Bacteria in the Small Intestine by Small Bowel Culture: Relationship with Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1321-1329.	1.1	159
16	Measurement of Gastrointestinal Transit. <i>Digestive Diseases and Sciences</i> , 2005, 50, 989-1004.	1.1	153
17	Methane on Breath Testing Is Associated with Constipation: A Systematic Review and Meta-analysis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1612-1618.	1.1	151
18	Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. <i>Therapeutic Advances in Chronic Disease</i> , 2013, 4, 223-231.	1.1	141

#	ARTICLE	IF	CITATIONS
19	Abnormal Breath Testing in IBS: A Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2441-2449.	1.1	140
20	Neomycin Improves Constipation-Predominant Irritable Bowel Syndrome in a Fashion That Is Dependent on the Presence of Methane Gas: Subanalysis of a Double-Blind Randomized Controlled Study. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1297-1301.	1.1	137
21	Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. <i>Digestive Diseases and Sciences</i> , 2002, 47, 2639-2643.	1.1	136
22	Methanobrevibacter smithii Is the Predominant Methanogen in Patients with Constipation-Predominant IBS and Methane on Breath. <i>Digestive Diseases and Sciences</i> , 2012, 57, 3213-3218.	1.1	127
23	Identification of A Prodromal Period in Crohn's Disease But Not Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2000, 95, 3458-3462.	0.2	124
24	A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 450-452.	0.5	124
25	Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS. <i>Digestive Diseases and Sciences</i> , 2008, 53, 169-174.	1.1	117
26	Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects. <i>PLoS ONE</i> , 2015, 10, e0126438.	1.1	114
27	How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach. <i>Current Gastroenterology Reports</i> , 2016, 18, 8.	1.1	113
28	Microbiome and Its Role in Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2020, 65, 829-839.	1.1	111
29	Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1278-1285.	1.1	103
30	Studying the Overlap Between IBS and GERD: A Systematic Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2006, 51, 2113-2120.	1.1	88
31	Effects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2067-2072.	1.1	86
32	Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1076-1087.	0.6	85
33	Review of rifaximin as treatment for SIBO and IBS. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 349-358.	1.9	84
34	AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. <i>Gastroenterology</i> , 2020, 159, 1526-1532.	0.6	84
35	Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome – An Update. <i>Frontiers in Psychiatry</i> , 2020, 11, 664.	1.3	82
36	A Combination of Rifaximin and Neomycin Is Most Effective in Treating Irritable Bowel Syndrome Patients With Methane on Lactulose Breath Test. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 547-550.	1.1	79

#	ARTICLE	IF	CITATIONS
37	A New Rat Model Links Two Contemporary Theories in Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2008, 53, 982-989.	1.1	76
38	Peppermint Oil Improves the Manometric Findings in Diffuse Esophageal Spasm. <i>Journal of Clinical Gastroenterology</i> , 2001, 33, 27-31.	1.1	75
39	Evaluating Breath Methane as a Diagnostic Test for Constipation-Predominant IBS. <i>Digestive Diseases and Sciences</i> , 2010, 55, 398-403.	1.1	74
40	Gas and the Microbiome. <i>Current Gastroenterology Reports</i> , 2013, 15, 356.	1.1	74
41	A 14-Day Elemental Diet Is Highly Effective in Normalizing the Lactulose Breath Test. <i>Digestive Diseases and Sciences</i> , 2004, 49, 73-77.	1.1	73
42	Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following <i>Campylobacter jejuni</i> Infection in a Rat Model. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1195-1205.	1.1	70
43	THE PRESENCE OF CONSTIPATION AND METHANE ON LACTULOSE BREATH TEST IN IBS SUBJECTS IS ASSOCIATED WITH LOWER SEROTONIN LEVELS COMPARED TO HYDROGEN ALONE. <i>American Journal of Gastroenterology</i> , 2003, 98, S72.	0.2	69
44	Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome. <i>American Journal of Medicine</i> , 2012, 125, 381-393.	0.6	68
45	The duodenal microbiome is altered in small intestinal bacterial overgrowth. <i>PLoS ONE</i> , 2020, 15, e0234906.	1.1	68
46	Age and the aging process significantly alter the small bowel microbiome. <i>Cell Reports</i> , 2021, 36, 109765.	2.9	67
47	Evidence- and Consensus-Based Practice Guidelines for the Diagnosis of Irritable Bowel Syndrome. <i>Archives of Internal Medicine</i> , 2001, 161, 2081.	4.3	65
48	Mapping the Segmental Microbiomes in the Human Small Bowel in Comparison with Stool: A REIMAGINE Study. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2595-2604.	1.1	65
49	Increased Prevalence of Irritable Bowel Syndrome in Patients With Gastroesophageal Reflux. <i>Journal of Clinical Gastroenterology</i> , 2002, 34, 221-224.	1.1	64
50	Breath Testing To Evaluate Lactose Intolerance in Irritable Bowel Syndrome Correlates With Lactulose Testing and May Not Reflect True Lactose Malabsorption. <i>American Journal of Gastroenterology</i> , 2003, 98, 2700-2704.	0.2	64
51	Methanogens in Human Health and Disease. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2012, 1, 28-33.	0.7	64
52	Aberrant TGF- $\beta$ 2 Production and Regulation in Metastatic Malignancy. <i>Growth Factors</i> , 1990, 3, 115-127.	0.5	62
53	Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 37-49.	1.9	61
54	Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. <i>BMC Gastroenterology</i> , 2012, 12, 55.	0.8	59

#	ARTICLE	IF	CITATIONS
55	Lactose Intolerance and the Role of the Lactose Breath Test. <i>American Journal of Gastroenterology</i> , 2010, 105, 1726-1728.	0.2	58
56	Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness. <i>BMC Gastroenterology</i> , 2013, 13, 46.	0.8	57
57	Measuring response in the gastrointestinal tract in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 700-706.	2.0	57
58	Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. <i>Gut Microbes</i> , 2019, 10, 22-33.	4.3	57
59	T1390 Rifaximin for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome: Short Term Treatment Leading to Long Term Sustained Response. <i>Gastroenterology</i> , 2008, 134, A-545.	0.6	56
60	Bacteria and irritable bowel syndrome: The evidence for small intestinal bacterial overgrowth. <i>Current Gastroenterology Reports</i> , 2006, 8, 305-311.	1.1	53
61	Role of Cytolethal Distending Toxin in Altered Stool Form and Bowel Phenotypes in a Rat Model of Post-infectious Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2012, 18, 434-442.	0.8	53
62	Intestinal <i>Methanobrevibacter smithii</i> but not total bacteria is related to diet-induced weight gain in rats. <i>Obesity</i> , 2013, 21, 748-754.	1.5	53
63	IBS Subjects with Methane on Lactulose Breath Test Have Lower Postprandial Serotonin Levels Than Subjects with Hydrogen. <i>Digestive Diseases and Sciences</i> , 2004, 49, 84-87.	1.1	51
64	Pathogen-Specific Risk of Celiac Disease Following Bacterial Causes of Foodborne Illness: A Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3242-3245.	1.1	50
65	Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. <i>American Journal of Gastroenterology</i> , 2019, 114, 1886-1893.	0.2	45
66	Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2455-2463.	1.1	43
67	Biomarkers of Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 20-26.	0.8	43
68	Esophageal Motor Dysfunction and Gastroesophageal Reflux Are Prevalent in Lung Transplant Candidates. <i>Annals of Thoracic Surgery</i> , 2010, 90, 1630-1636.	0.7	42
69	Placebo Effect in Clinical Trial Design for Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2014, 20, 163-170.	0.8	42
70	In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 236-241.	1.1	41
71	Ultraviolet A light effectively reduces bacteria and viruses including coronavirus. <i>PLoS ONE</i> , 2020, 15, e0236199.	1.1	40
72	Estimating the Contribution of Acute Gastroenteritis to the Overall Prevalence of Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2012, 18, 200-204.	0.8	38

#	ARTICLE	IF	CITATIONS
73	ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. <i>World Journal of Gastroenterology</i> , 2010, 16, 3680.	1.4	38
74	Antibiotics for Irritable Bowel Syndrome: Rationale and Current Evidence. <i>Current Gastroenterology Reports</i> , 2012, 14, 439-445.	1.1	37
75	Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage. <i>BMC Gastroenterology</i> , 2016, 16, 67.	0.8	37
76	Visceroptosis of the bowel in the hypermobility type of Ehlers-Danlos syndrome: Presentation of a rare manifestation and review of the literature. <i>European Journal of Medical Genetics</i> , 2012, 55, 548-551.	0.7	36
77	Gut Microbiota Dysbiosis in Functional Dyspepsia. <i>Microorganisms</i> , 2020, 8, 691.	1.6	36
78	Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 672-675.	1.1	35
79	The Effect of Rifaximin on Gut Flora and Staphylococcus Resistance. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1676-1682.	1.1	35
80	Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1480-1485.	1.1	35
81	Polycystic Ovary Syndrome Is Associated with an Increased Prevalence of Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1085-1089.	1.1	34
82	Fecal Incontinence in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1280-1290.	0.9	34
83	Intestinal methane production in obese individuals is associated with a higher body mass index. <i>Gastroenterology and Hepatology</i> , 2012, 8, 22-8.	0.2	33
84	Quantitative sequencing clarifies the role of disruptor taxa, oral microbiota, and strict anaerobes in the human small-intestine microbiome. <i>Microbiome</i> , 2021, 9, 214.	4.9	31
85	New Clinical Method for Distinguishing D-IBS from Other Gastrointestinal Conditions Causing Diarrhea: The LA/IBS Diagnostic Strategy. <i>Digestive Diseases and Sciences</i> , 2010, 55, 145-149.	1.1	30
86	Proton Pump Inhibitor Therapy Does Not Affect Hydrogen Production on Lactulose Breath Test in Subjects with IBS. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2302-2308.	1.1	30
87	Apple Sauce Improves Detection of Esophageal Motor Dysfunction During High-Resolution Manometry Evaluation of Dysphagia. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1723-1728.	1.1	30
88	Irritable bowel syndrome: Bacterial overgrowth—What's known and what to do. <i>Current Treatment Options in Gastroenterology</i> , 2007, 10, 328-337.	0.3	29
89	Gender distribution in irritable bowel syndrome is proportional to the severity of constipation relative to diarrhea. <i>Gender Medicine</i> , 2010, 7, 240-246.	1.4	29
90	Evaluating a Bacterial Hypothesis in IBS Using a Modification of Koch's Postulates: Part 1. <i>American Journal of Gastroenterology</i> , 2010, 105, 718-721.	0.2	29

#	ARTICLE	IF	CITATIONS
91	Acute and Chronic Histological Changes of the Small Bowel Secondary to <i>C. jejuni</i> Infection in a Rat Model for Post-Infectious IBS. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2575-2584.	1.1	29
92	Optimizing microbiome sequencing for small intestinal aspirates: validation of novel techniques through the REIMAGINE study. <i>BMC Microbiology</i> , 2019, 19, 239.	1.3	28
93	Inflammation and Microflora. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 69-85.	1.0	27
94	Effect of repeated <i>Campylobacter jejuni</i> infection on gut flora and mucosal defense in a rat model of post infectious functional and microbial bowel changes. <i>Neurogastroenterology and Motility</i> , 2013, 25, 529.	1.6	26
95	Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity. <i>Obesity</i> , 2016, 24, 576-582.	1.5	26
96	Breath Testing for Small Intestinal Bacterial Overgrowth: Should We Bother?. <i>American Journal of Gastroenterology</i> , 2016, 111, 307-308.	0.2	24
97	Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3115-3121.	1.1	24
98	Is small intestinal bacterial overgrowth involved in the pathogenesis of functional dyspepsia?. <i>Medical Hypotheses</i> , 2017, 106, 26-32.	0.8	23
99	Dyssynergic Defecation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1065-1073.	0.9	23
100	Effects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes. <i>Digestive Diseases and Sciences</i> , 2022, 67, 224-232.	1.1	23
101	Antibiotics for the treatment of irritable bowel syndrome. <i>Gastroenterology and Hepatology</i> , 2011, 7, 455-93.	0.2	23
102	An Approach to the Patient With Chronic Undiagnosed Abdominal Pain. <i>American Journal of Gastroenterology</i> , 2019, 114, 726-732.	0.2	21
103	Severity of Dyspeptic Symptoms Correlates with Delayed and Early Variables of Gastric Emptying. <i>Digestive Diseases and Sciences</i> , 2012, 58, 478-87.	1.1	20
104	Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway. <i>F1000Research</i> , 2016, 5, 606.	0.8	20
105	Adverse events appear to unblind clinical trials in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2014, 26, 482-488.	1.6	19
106	Small Intestinal Bacterial Overgrowth: A Possible Association with Fibromyalgia. <i>Journal of Musculoskeletal Pain</i> , 2001, 9, 105-113.	0.3	18
107	Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 689-699.	1.4	18
108	Postprandial improvement of gastric dysrhythmias in patients with type II diabetes: identification of responders and nonresponders. <i>Digestive Diseases and Sciences</i> , 2001, 46, 705-712.	1.1	17

#	ARTICLE	IF	CITATIONS
109	Mo1641 Efficacy and Tolerability of Linaclotide and Plecanatide in Treating Irritable Bowel Syndrome With Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC): A Meta-Analysis. <i>Gastroenterology</i> , 2016, 150, S739.	0.6	16
110	Acute appendicitis is associated with appendiceal microbiome changes including elevated <i>Campylobacter jejuni</i> levels. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000412.	1.1	16
111	Evidence-based management of irritable bowel syndrome with diarrhea. <i>American Journal of Managed Care</i> , 2018, 24, S35-S46.	0.8	16
112	An Evidence-Based Treatment Algorithm for IBS Based on a Bacterial/SIBO Hypothesis: Part 2. <i>American Journal of Gastroenterology</i> , 2010, 105, 1227-1230.	0.2	15
113	Antibiotic Prophylaxis Prevents the Development of a Post-Infectious Phenotype in a New Rat Model of Post-Infectious IBS. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1962-1966.	1.1	15
114	Influence of Dietary Restriction on Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2019, 114, 212-220.	0.2	15
115	Rifaximin, a Non-Absorbable Antibiotic, Improves the Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2005, 100, S324.	0.2	15
116	Pre-cebo. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 686-690.	1.1	14
117	Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	14
118	High Prevalence of Small Intestinal Bacterial Overgrowth among Functional Dyspepsia Patients. <i>Digestive Diseases</i> , 2021, 39, 382-390.	0.8	14
119	A Single Fasting Exhaled Methane Level Correlates With Fecal Methanogen Load, Clinical Symptoms and Accurately Detects Intestinal Methanogen Overgrowth. <i>American Journal of Gastroenterology</i> , 2022, 117, 470-477.	0.2	14
120	A High-resolution View of Achalasia. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 644-651.	1.1	13
121	Relationships Among the Lactulose Breath Test, Intestinal Gas Volume, and Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2059-2066.	1.1	13
122	Factor Analysis Demonstrates a Symptom Cluster Related to Methane and Non-methane Production in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 40-44.	1.1	12
123	Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 973-983.	1.9	12
124	Intestinal methane production is associated with decreased weight loss following bariatric surgery. <i>Obesity Research and Clinical Practice</i> , 2016, 10, 728-733.	0.8	12
125	Breath Test Gas Patterns in Inflammatory Bowel Disease with Concomitant Irritable Bowel Syndrome-Like Symptoms: A Controlled Large-Scale Database Linkage Analysis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2388-2396.	1.1	12
126	Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00144.	1.3	12

#	ARTICLE	IF	CITATIONS
127	Accurate Identification of Excessive Methane Gas Producers by a Single Fasting Measurement of Exhaled Methane: A Large-scale Database Analysis ACG Category Award. <i>American Journal of Gastroenterology</i> , 2015, 110, S759-S760.	0.2	12
128	Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. <i>Gastroenterology and Hepatology</i> , 2009, 5, 435-42.	0.2	12
129	Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome a double-blind, randomized, placebo-controlled study. <i>American Journal of Gastroenterology</i> , 2003, 98, 412-419.	0.2	11
130	History of Tonsillectomy Is Associated With Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 912.	1.1	11
131	Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts. <i>Clinical Rheumatology</i> , 2021, 40, 2277-2284.	1.0	11
132	Immunization with cytolethal distending toxin B produces autoantibodies to vinculin and small bowel bacterial changes in a rat model of postinfectious irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13875.	1.6	11
133	Smoking has disruptive effects on the small bowel luminal microbiome. <i>Scientific Reports</i> , 2022, 12, 6231.	1.6	11
134	Healthy control subjects are poorly defined in case-control studies of irritable bowel syndrome. <i>Annals of Gastroenterology</i> , 2015, 28, 87-93.	0.4	10
135	Irritable Bowel Syndrome in Pregnancy. <i>American Journal of Gastroenterology</i> , 2021, 116, 480-490.	0.2	9
136	Evaluation of peripapillary lymphocytosis and lymphocytic esophagitis in adult inflammatory bowel disease. <i>Gastroenterology and Hepatology</i> , 2013, 9, 505-11.	0.2	9
137	Duodenal microbiome changes in postmenopausal women: effects of hormone therapy and implications for cardiovascular risk. <i>Menopause</i> , 2022, 29, 264-275.	0.8	9
138	Serum sTREM-1 as a Surrogate Marker of Treatment Outcome in Patients with Peptic Ulcer Disease. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3590-3595.	1.1	8
139	Tu2110 Circulating Antibodies to Cytolethal Distending Toxin B Correlate With the Development of Small Intestinal Bacterial Overgrowth in a Rat Model of Post-Infectious IBS. <i>Gastroenterology</i> , 2013, 144, S-931-S-932.	0.6	8
140	Lovastatin Lactone Inhibits Methane Production in Human Stool Homogenates. <i>American Journal of Gastroenterology</i> , 2015, 110, S753.	0.2	8
141	Su1210 SYN-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, Lowered Breath Methane and Improved Stool Frequency in Patients With IBS-C: Results of a Multi-Center Randomized Double-Blind Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2016, 150, S496-S497.	0.6	8
142	A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome. <i>Clinical Therapeutics</i> , 2016, 38, 1638-1652.e9.	1.1	8
143	Comparing the rates of methane production in patients with and without appendectomy: results from a large-scale cohort. <i>Scientific Reports</i> , 2020, 10, 867.	1.6	8
144	Endotracheal Application of Ultraviolet A Light in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus 2: A First-in-Human Study. <i>Advances in Therapy</i> , 2021, 38, 4556-4568.	1.3	8

#	ARTICLE	IF	CITATIONS
145	475i Rifaximin Treatment for 2 Weeks Provides Acute and Sustained Relief Over 12 Weeks of IBS Symptoms in Non-Constipated Irritable Bowel Syndrome: Results From 2 North American Phase 3 Trials (Target 1 and Target 2). <i>Gastroenterology</i> , 2010, 138, S-64-S-65.	0.6	7
146	A Smartphone Application Using Artificial Intelligence Is Superior To Subject Self-Reporting When Assessing Stool Form. <i>American Journal of Gastroenterology</i> , 2022, 117, 1118-1124.	0.2	7
147	Small Bowel Culture Confirms the Presence of Small Intestinal Bacterial Overgrowth in a Subset of IBS Subjects. <i>Gastroenterology</i> , 2011, 140, S-152.	0.6	6
148	Breath Testing for Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Metaanalysis. <i>American Journal of Gastroenterology</i> , 2015, 110, S762-S763.	0.2	6
149	Bacterial concepts in irritable bowel syndrome. <i>Reviews in Gastroenterological Disorders</i> , 2005, 5 Suppl 3, S3-9.	0.6	6
150	Do antibiotics influence IBS?. <i>American Journal of Gastroenterology</i> , 2002, 97, 2681-2681.	0.2	5
151	Gastroesophageal Reflux Reported on Esophagram Does Not Correlate with pH Monitoring and High-resolution Esophageal Manometry. <i>American Surgeon</i> , 2014, 80, 1026-1029.	0.4	5
152	Understanding Breath Tests for Small Intestinal Bacterial Overgrowth. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1362-1363.	2.4	5
153	Campylobacter infection and the link with Irritable Bowel Syndrome: on the pathway towards a causal association. <i>Pathogens and Disease</i> , 2022, 80, .	0.8	5
154	Small Intestine Bacterial Overgrowth Can Form an Indigenous Proinflammatory Environment in the Duodenum: A Prospective Study. <i>Microorganisms</i> , 2022, 10, 960.	1.6	5
155	Probiotics for Antibiotic-Associated Diarrhea: PLACIDE Swings the Pendulum. <i>Gastroenterology</i> , 2014, 146, 1822-1823.	0.6	4
156	Mo1865 Prevalence of Excessive Intestinal Methane Production and Its Variability With Age and Gender: A Large-Scale Database Analysis. <i>Gastroenterology</i> , 2015, 148, S-729-S-730.	0.6	4
157	450 Hydrogen- and Methane- Based Breath Testing (BT) in Gastrointestinal (GI) Disorders: Report of the North American Consensus Meeting. <i>Gastroenterology</i> , 2016, 150, S97.	0.6	4
158	Measurement of Hydrogen Sulfide during Breath Testing Correlates to Patient Symptoms. <i>Gastroenterology</i> , 2017, 152, S205-S206.	0.6	4
159	Response to Dr. Parisi et al.. <i>American Journal of Gastroenterology</i> , 2003, 98, 2573-2574.	0.2	3
160	Concomitant Methane and Hydrogen Production in Humans is Associated With a Higher Body Mass Index. <i>Gastroenterology</i> , 2011, 140, S-335.	0.6	3
161	Importance of Diarrhea in Evaluating Constipation in Irritable Bowel Syndrome Clinical Studies. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 790-793.	1.1	3
162	A definitive blood test for post-infectious irritable bowel syndrome?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1197-1199.	1.4	3

#	ARTICLE	IF	CITATIONS
163	Gastrointestinal Infection with <i>Campylobacter jejuni</i> 81â€™176 Produces Altered Bowel Function and Bacterial Overgrowth in Rats. <i>American Journal of Gastroenterology</i> , 2006, 101, S472.	0.2	3
164	The Prevalence of Irritable Bowel Syndrome in Patients With Typical Symptoms Referred to the Gastroenterologist: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2015, 110, S758.	0.2	3
165	T2085 Methane on Breath Testing is Associated With Constipation: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2010, 138, S-629.	0.6	2
166	Tu2030 Quantitation of Bacteria in Duodenal Aspirates by qPCR Appears to Identify Viable Organisms in IBS. <i>Gastroenterology</i> , 2013, 144, S-908.	0.6	2
167	Tu2029 Deep Sequencing Reveals That the Microbiome of the Human Duodenum Is Unique and Unrelated to Stool Bacterial Profiling. <i>Gastroenterology</i> , 2013, 144, S-908.	0.6	2
168	Rifaximin Repeat Treatment in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Produced No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. <i>American Journal of Gastroenterology</i> , 2015, 110, S761.	0.2	2
169	Tu1804 Anti-Vinculin and Anti-CdtB Antibodies in Mexican Subjects: A Case Control Study. <i>Gastroenterology</i> , 2016, 150, S952.	0.6	2
170	Reply. <i>Gastroenterology</i> , 2016, 150, 278-279.	0.6	2
171	Autoimmunity as a Potential Cause of Post-Infectious Gut Dysmotility: A Longitudinal Observation. <i>American Journal of Gastroenterology</i> , 2017, 112, 656-657.	0.2	2
172	Safety and Tolerability of High-Resolution Esophageal Manometry: A Large Database Analysis. <i>Gastroenterology</i> , 2017, 152, S325.	0.6	2
173	Sa1219 - Validation of a 4-Gas Device for Breath Testing in the Determination of Small Intestinal Bacterial Overgrowth. <i>Gastroenterology</i> , 2018, 154, S-281.	0.6	2
174	Ultraviolet-A light reduces cellular cytokine release from human endotracheal cells infected with Coronavirus. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 35, 102457.	1.3	2
175	Intestinal <i>Methanobrevibacter smithii</i> but Not Total Bacteria Is Related to Diet-Induced Weight Gain in Rats. <i>Obesity</i> , 0, , .	1.5	2
176	Rifaximin and Neomycin in the Treatment of Constipation IBS with Methane as a Biomarker on Breath Testing: Presidential Poster. <i>American Journal of Gastroenterology</i> , 2013, 108, S563.	0.2	2
177	The Response of the Rodent Gut Microbiome to Broad-Spectrum Antibiotics Is Different in Males and Females. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	2
178	Response to Dr. Riordan et al.. <i>American Journal of Gastroenterology</i> , 2001, 96, 2507-2508.	0.2	1
179	Healthy Controls Are Not Appropriately Identified for Comparison to Irritable Bowel Syndrome in Case Control Studies. <i>Gastroenterology</i> , 2011, 140, S-799.	0.6	1
180	Methane-Producing Subjects Have Higher Serum Glucose Levels During Oral Glucose Challenge Than Non-Methane Producers. <i>Gastroenterology</i> , 2011, 140, S-193.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Lymphocytic Esophagitis is Uncommon in Adult Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2011, 140, S-228.	0.6	1
182	Time to Onset and Durability of Relief in Non-Constipation IBS Patients Over 12 Weeks Following a 2-Week Course of Rifaximin. <i>Gastroenterology</i> , 2011, 140, S-605.	0.6	1
183	Daily Variation of Bowel Habits Predicts a Diagnosis of IBS Among Patients Referred to a General Gastroenterologist for Evaluation of Chronic Diarrhea: Validation of the LA/IBS Diagnostic Strategy. <i>Gastroenterology</i> , 2011, 140, S-800.	0.6	1
184	Recorded Lower Esophageal Pressures as a Function of Electronic Sleeve Placement and Location of Gastric Pressure Measurement in Patients With Hiatal Hernia. <i>Journal of Neurogastroenterology and Motility</i> , 2013, 19, 479-484.	0.8	1
185	SYN-010 Modified-Release Lovastatin Does Not Significantly Alter Lipid Parameters at Doses that Reduce Methane and Alleviate Symptoms in Patients Suffering Irritable Bowel Syndrome with Constipation (IBS-C). <i>American Journal of Gastroenterology</i> , 2016, 111, S256-S257.	0.2	1
186	Mo1314 Effect of Rifaximin Treatment on Anti-Vinculin Antibodies in IBS With Diarrhea. <i>Gastroenterology</i> , 2016, 150, S695.	0.6	1
187	Cytolethal Distending Toxin B (CdtB) Exposure Alone is Sufficient to Precipitate Autoimmunity and Changes to the Small Intestinal Microbiome in a Rat Model of Post-Infectious IBS. <i>Gastroenterology</i> , 2017, 152, S621.	0.6	1
188	Phenotype and Antibiotic Response in Patients With Flat Line Breath Test Results: A Large Scale Database Analysis. <i>American Journal of Gastroenterology</i> , 2018, 113, S261.	0.2	1
189	Sa1912 "Revealing the Entire Intestinal Microbiota and Its Associations to the Genetic, Immunologic, and Neuroendocrine Ecosystems: Methodology for the Reimagine Study. <i>Gastroenterology</i> , 2019, 156, S-450.	0.6	1
190	Su1949 "Small Intestinal Aspirates Require Specific Treatment to Optimize Microbial Analysis: Validation of a Novel Technique from the Reimagine Study. <i>Gastroenterology</i> , 2019, 156, S-670.	0.6	1
191	Declining Rates of Referral for Irritable Bowel Syndrome Without Constipation at a Tertiary Care Center. <i>Digestive Diseases and Sciences</i> , 2019, 64, 182-188.	1.1	1
192	Small Intestinal Bacterial Overgrowth. , 2015, , 125-136.		1
193	Proton Pump Inhibitors Do Not Affect the Lactulose Hydrogen Breath Test in IBS Subjects. <i>American Journal of Gastroenterology</i> , 2009, 104, S495.	0.2	1
194	Pathogen-specific Risk of Functional Gastrointestinal Disorders, Gastroesophageal Reflux Disease and Celiac Disease Following Acute Enteric Infection. <i>American Journal of Gastroenterology</i> , 2011, 106, S512.	0.2	1
195	Rectal Hypersensitivity in Patients with Irritable Bowel Syndrome Compared to Healthy Control: A Systemic Review of Literature. <i>American Journal of Gastroenterology</i> , 2012, 107, S714.	0.2	1
196	Rise in Hydrogen Production During Lactulose Breath Test Does Not Represent Oro-Cecal Transit Due to Lag in Peak Fermentation. <i>American Journal of Gastroenterology</i> , 2012, 107, S716.	0.2	1
197	Anti-vinculin Antibodies: Multicenter Validation of a Diagnostic Blood Test for Irritable Bowel Syndrome: ACG Governors Award for Excellence in Clinical Research. <i>American Journal of Gastroenterology</i> , 2013, 108, S571.	0.2	1
198	Lactulose Breath Testing Predicts the Response to Rifaximin. <i>American Journal of Gastroenterology</i> , 2017, 112, S227.	0.2	1

#	ARTICLE	IF	CITATIONS
199	Unique Differences in Breath Test Gas Patterns in Inflammatory Bowel Disease (IBD) Compared to Non-IBD Patients: A Large-Scale Database Linkage Analysis. <i>American Journal of Gastroenterology</i> , 2018, 113, S381-S382.	0.2	1
200	Significant Overlap between IBS and GERD. <i>American Journal of Gastroenterology</i> , 2005, 100, S324.	0.2	1
201	The Efficacy of the GLP-1 Agonist Exenatide in the Treatment of Short Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2007, 102, S201-S202.	0.2	1
202	Identification of Rumination with Impedance Manometry and High-Resolution Manometry. <i>American Journal of Gastroenterology</i> , 2008, 103, S29.	0.2	1
203	Increased Risk of IBD Among Military Personnel with IBS. <i>American Journal of Gastroenterology</i> , 2010, 105, S460.	0.2	1
204	The Treatment of Patients With Irritable Bowel Syndrome: Review of the Latest Data From the 2010 DDW Meeting. <i>Gastroenterology and Hepatology</i> , 2010, 6, 1-15.	0.2	1
205	Ultraviolet-A light increases mitochondrial anti-viral signaling protein in confluent human tracheal cells via cell-cell signaling. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2022, 226, 112357.	1.7	1
206	Response to Drs. Mishkin. <i>American Journal of Gastroenterology</i> , 2001, 96, 2505-2506.	0.2	0
207	A Systematic Review of Diagnostic Testing for Small Intestinal Bacterial Overgrowth. <i>American Journal of Gastroenterology</i> , 2007, 102, S202.	0.2	0
208	Nightly Tegaserod Prevents the Clinical Recurrence of Bacterial Overgrowth Symptoms. <i>American Journal of Gastroenterology</i> , 2007, 102, S499.	0.2	0
209	The Responsiveness and Validity of a Binary Weekly Recall Question and the Proposed FDA Composite Endpoint as Measures of Daily Symptom Severity in Non-Constipation Irritable Bowel Syndrome: Results of TARGET 1 and TARGET 2. <i>American Journal of Gastroenterology</i> , 2010, 105, S494.	0.2	0
210	Rifaximin Treatment Consistently Demonstrated Relief Across Daily Symptoms in Patients with Non-Constipation Irritable Bowel Syndrome: Results from 2 Phase 3 Trials (TARGET 1 and TARGET 2). <i>American Journal of Gastroenterology</i> , 2010, 105, S483-S484.	0.2	0
211	Increased Risk for IGE Among Those with IBS. <i>American Journal of Gastroenterology</i> , 2010, 105, S494.	0.2	0
212	Antibodies to <i>Campylobacter jejuni</i> Cytolethal Distending Toxin Subunit B (CDT-B) Bind Enteric Neural Elements in Uninfected Mice Suggesting Molecular Mimicry. <i>Gastroenterology</i> , 2011, 140, S-521.	0.6	0
213	Antibodies to an 18-Residue Peptide of Cdt Are Found in the Serum of Rats in a Model of Post-Infectious IBS. <i>Gastroenterology</i> , 2011, 140, S-371.	0.6	0
214	Expression of B-Defensin-2 and Other PRO-Inflammatory Mediators Notable in IBS Are Increased in Rat Mucosa During Acute <i>Campylobacter jejuni</i> Infection. <i>Gastroenterology</i> , 2011, 140, S-602.	0.6	0
215	Validating a New Genomic Test for Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2011, 140, S-798.	0.6	0
216	Dietary Fat Content Influences the Natural Colonization of Sprague-Dawley Rats With <i>Methanobrevibacter smithii</i> . <i>Gastroenterology</i> , 2011, 140, S-333.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Repeat Exposure to C. Jejuni Increases the Development of SIBO in a Rat Model of Post-Infectious IBS. <i>Gastroenterology</i> , 2011, 140, S-602-S-603.	0.6	0
218	1134 The Utility of Measuring Anti-Cytolethal Distending Toxin B and Anti-Vinculin Antibodies in a Tertiary Care Motility Practice: A Free Range Experience. <i>Gastroenterology</i> , 2016, 150, S230.	0.6	0
219	257 Assessment of Anti-Vinculin and Anti-CdtB Antibodies in IBS Subtypes. <i>Gastroenterology</i> , 2016, 150, S62.	0.6	0
220	Autoimmunity and Irritable Bowel Syndrome: New Pathophysiology. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2016, 3, 41-45.	0.7	0
221	Mo1311 Evaluating the Safety and Efficacy of Eluxadoline for Treating Diarrhea-Predominant Irritable Bowel Syndrome: A Meta-Analysis. <i>Gastroenterology</i> , 2016, 150, S694.	0.6	0
222	Tu1750 Gastrointestinal (GI) Symptoms Associated With Excessive Intestinal Methane Production in the Pediatric Population: A Large Database Analysis. <i>Gastroenterology</i> , 2016, 150, S933-S934.	0.6	0
223	Mo1319 Syn-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, May Improve Constipation by Inhibiting Enzymes in the Archaeal Methanogenesis Pathway: Results of Computational M. Smithii Enzyme-Ligand Docking Experiments. <i>Gastroenterology</i> , 2016, 150, S696-S697.	0.6	0
224	Su1793 Breath Methane and Hydrogen Composition in Inflammatory Bowel Disease (IBD) Is Strikingly Different From Non-IBD Patients and Is Associated With IBD-Associated Genes: A Large-Scale Database Linkage Analysis. <i>Gastroenterology</i> , 2016, 150, S553.	0.6	0
225	Examination of the effects of breath hydrogen and methane levels on the EC/IR II. <i>Journal of the Canadian Society of Forensic Science</i> , 2017, 50, 125-130.	0.7	0
226	Sustained Response and Predictors of Sustained Response in Patients who Respond to Multiple Courses of Rifaximin for Diarrhea-Predominant Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, S918.	0.6	0
227	Declining Rates of Referral to Tertiary Care Center for IBS-D. <i>Gastroenterology</i> , 2017, 152, S720.	0.6	0
228	Characterization of Abdominal Pain Response in Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Rifaximin. <i>Gastroenterology</i> , 2017, 152, S915.	0.6	0
229	Responders Analysis in Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Treated With Rifaximin. <i>American Journal of Gastroenterology</i> , 2017, 112, S236.	0.2	0
230	Small Intestinal Bacterial Overgrowth. , 2018, , 333-342.		0
231	High-Resolution Manometry Anorectal Manometry. <i>American Journal of Gastroenterology</i> , 2006, 101, S218.	0.2	0
232	Rifaximin Is Superior to Other Antibiotics in Treating and Retreating Bacterial Overgrowth in IBS, Supporting a Lack of Bacterial Resistance Development. <i>American Journal of Gastroenterology</i> , 2006, 101, S475.	0.2	0
233	In the Treatment of IBS, the Clinical Response to Rifaximin Is Determined by the Normalization of the Lactulose Breath Test. <i>American Journal of Gastroenterology</i> , 2006, 101, S474-S475.	0.2	0
234	Methane Production in IBS Subjects Is Associated with a Constellation of Symptoms: Not Just Constipation. <i>American Journal of Gastroenterology</i> , 2007, 102, S499-S500.	0.2	0

#	ARTICLE	IF	CITATIONS
235	Severity of Irritable Bowel Syndrome-Related Symptoms Predicts Clinical Response to the Nonsystemic Antibiotic Rifaximin. American Journal of Gastroenterology, 2008, 103, S463.	0.2	0
236	Evaluating Breath Methane as a Diagnostic Test for Constipation Predominant IBS. American Journal of Gastroenterology, 2008, 103, S458.	0.2	0
237	A Combination of Rifaximin and Neomycin Is Most Effective in Treating Patients with Methane on Lactulose Breath Test. American Journal of Gastroenterology, 2008, 103, S465-S466.	0.2	0
238	Validation of a Simple Tool (Constipation Minus Diarrhea) for Evaluating Constipation Symptom Outcomes in IBS. American Journal of Gastroenterology, 2009, 104, S495-S496.	0.2	0
239	Incontinence and Anal Sphincter Pressure Predicts Rectal Sensitivity During High Resolution Anorectal Manometry. American Journal of Gastroenterology, 2009, 104, S485.	0.2	0
240	New Onset Gastroesophageal Reflux Disease After Acute Gastroenteritis: A Case of Post-Infectious GERD?. American Journal of Gastroenterology, 2009, 104, S367.	0.2	0
241	The Methanobrevibacter smithii Concentration in Stool of Subjects with Constipation Predominant IBS is Directly Correlated with Methane on Lactulose Breath Test. American Journal of Gastroenterology, 2010, 105, S500.	0.2	0
242	Defining Normal Bowel Function Relative to GI Disease: A Systematic Review of the Literature. American Journal of Gastroenterology, 2010, 105, S501.	0.2	0
243	Understanding Harm in the Pharmacotherapy of Irritable Bowel Syndrome with Diarrhea. American Journal of Gastroenterology, 2011, 106, S496.	0.2	0
244	Evaluation of Rifaximin Efficacy in Non C-IBS Patients by Baseline Disease Severity: Subanalysis of the TARGET 1 and TARGET 2 Studies. American Journal of Gastroenterology, 2011, 106, S505-S506.	0.2	0
245	Gender of Gastroenterologist and Years in Practice are Important in Drug Selection for D-IBS. American Journal of Gastroenterology, 2012, 107, S715.	0.2	0
246	Responsiveness of a Tri-Component Endpoint in Non-Constipation Irritable Bowel Syndrome: Pooled Results from Two Phase 3 Trials, TARGET 1 and TARGET 2. American Journal of Gastroenterology, 2012, 107, S712.	0.2	0
247	The Effect of Rifaximin on Staphylococcus Species in the Stool. American Journal of Gastroenterology, 2012, 107, S228.	0.2	0
248	Diagnosis of Pellagra Should Be Considered in Patients Suspicious for Crohn's. American Journal of Gastroenterology, 2012, 107, S379.	0.2	0
249	The Effect of Dried Plum on Targeted Gut Flora and Host Gene Expression in a Rat Model of Post-infectious IBS. American Journal of Gastroenterology, 2014, 109, S537.	0.2	0
250	Stack of Coins on Manometry: Type 3 Achalasia Complicated by Severe Esophageal Diverticulosis. American Journal of Gastroenterology, 2015, 110, S269-S270.	0.2	0
251	Antibiotic Susceptibility of Skin Swab Staphylococcus Isolates From Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Treated With Repeat Courses of Rifaximin Showed No Evidence of Resistance. American Journal of Gastroenterology, 2015, 110, S751.	0.2	0
252	Improvements over Time in Individual Diarrhea-Predominant Irritable Bowel Syndrome Symptoms (IBS-D) with Rifaximin Repeat Treatment. American Journal of Gastroenterology, 2016, 111, S240.	0.2	0

#	ARTICLE	IF	CITATIONS
253	Safety and Tolerability of Rifaximin in the Treatment of Irritable Bowel Syndrome (IBS): A Pooled Analysis of 4 Randomized, Placebo-Controlled Trials. American Journal of Gastroenterology, 2016, 111, S253.	0.2	0
254	Development and Seroconversion of Anti-Cytolethal Distending Toxin(CdtB) and Anti-Vinculin Antibodies in a Patient with Evolving Post-infectious IBS. American Journal of Gastroenterology, 2016, 111, S807.	0.2	0
255	Efficacy of Rifaximin on Bowel Movement Urgency in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D): A Pooled Analysis of 3 Phase 3 Trials. American Journal of Gastroenterology, 2016, 111, S253-S254.	0.2	0
256	Does Bacterial Overgrowth Affect Breath Alcohol Levels on DUI Testing?: 2016 ACG Presidential Poster Award. American Journal of Gastroenterology, 2016, 111, S467.	0.2	0
257	Assessing the Efficacy of Rifaximin in Diarrhea-Predominant Irritable Syndrome (IBS-D): A Post hoc Analysis of 2 Phase 3, Randomized, Placebo-Controlled Trials. American Journal of Gastroenterology, 2017, 112, S254.	0.2	0
258	Lactulose Breath Testing Predicts Response to Rifaximin for Cardinal Irritable Bowel Syndrome With Diarrhea (IBS-D). American Journal of Gastroenterology, 2018, 113, S270.	0.2	0
259	Irritable bowel syndrome: Bacterial overgrowth—What’s known and what to do. Current Treatment Options in Cardiovascular Medicine, 2007, 10, 328-337.	0.4	0
260	Case studies of antibiotic therapy in the management of functional gastrointestinal disorders. Gastroenterology and Hepatology, 2007, 3, 1-12.	0.2	0
261	Update on Irritable Bowel Syndrome Diagnostics and Therapeutics. Gastroenterology and Hepatology, 2016, 12, 442-5.	0.2	0